Published in Kidney Int on April 01, 2002
Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int (2009) 1.77
Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest (2005) 1.39
Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir Res (2010) 1.01
The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol (2009) 0.96
Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int (2012) 0.95
Role of TGF-β in a mouse model of high turnover renal osteodystrophy. J Bone Miner Res (2014) 0.85
Achievements and challenges in bioartificial kidney development. Fibrogenesis Tissue Repair (2010) 0.84
High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol Dial Transplant (2012) 0.77
Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation. J Bone Miner Metab (2013) 0.77
New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Metab (2006) 0.75
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med (2009) 3.69
Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol (2005) 2.27
Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol (2004) 2.21
The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol (2008) 1.99
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int (2005) 1.96
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis (2010) 1.93
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int (2003) 1.82
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol (2005) 1.54
Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem (2008) 1.53
Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.52
RGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury. Kidney Int (2011) 1.51
Salvage of thrombosed dialysis access grafts with venous anastomosis stents. Kidney Int (2005) 1.50
A microRNA expression signature of osteoclastogenesis. Blood (2011) 1.49
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant (2011) 1.46
BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol (2003) 1.45
Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol (2015) 1.42
Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem (2004) 1.40
CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol (2009) 1.40
Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol (2006) 1.37
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol (2008) 1.35
Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis (2007) 1.32
Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int (2003) 1.29
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Admixture mapping of coronary artery calcified plaque in African Americans with type 2 diabetes mellitus. Circ Cardiovasc Genet (2012) 1.22
Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int (2007) 1.17
Vitamin D and kidney disease. Clin J Am Soc Nephrol (2008) 1.16
Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol (2004) 1.10
Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem (2003) 1.07
PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem (2002) 1.06
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol (2008) 1.06
Relationships between calcified atherosclerotic plaque and bone mineral density in African Americans with type 2 diabetes. J Bone Miner Res (2011) 1.06
Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol (2004) 1.03
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol (2013) 1.03
Adenovirus mediated BMP-13 gene transfer induces chondrogenic differentiation of murine mesenchymal progenitor cells. J Bone Miner Res (2004) 1.01
Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem (2003) 0.99
Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab (2011) 0.99
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant (2012) 0.99
The BMP-7-Smad1/5/8 pathway promotes kidney repair after obstruction induced renal injury. J Urol (2011) 0.99
Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis (2008) 0.97
Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res (2009) 0.96
The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol (2009) 0.96
The urinary response to an oral oxalate load in recurrent calcium stone formers. J Urol (2003) 0.94
Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant (2007) 0.93
The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int (2003) 0.93
Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J Bone Miner Res (2003) 0.92
Bone morphogenetic protein signaling in articular chondrocyte differentiation. Biochem Biophys Res Commun (2003) 0.92
Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens (2004) 0.91
A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin (2015) 0.90
Vascular smooth muscle cells in the pathogenesis of vascular calcification. Circ Res (2009) 0.88
Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int (2004) 0.88
Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis (2013) 0.88
Formation of downhill esophageal varices as a rare but serious complication of hemodialysis access: a case report and comprehensive literature review. Clin Exp Nephrol (2008) 0.88
Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study. J Clin Endocrinol Metab (2013) 0.88
Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Semin Dial (2005) 0.88
Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling. Int Orthop (2007) 0.86
Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption. BMC Cell Biol (2004) 0.86
Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens (2002) 0.85
Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells. J Cell Biochem (2003) 0.84
Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol (2004) 0.84
Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. BMC Nephrol (2012) 0.84
Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int (2002) 0.84
Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem (2013) 0.84
Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria. Nephron Exp Nephrol (2004) 0.84
Safety and efficacy of transjugular renal biopsy performed by interventional nephrologists. Semin Dial (2010) 0.83
Connections between vascular calcification and progression of chronic kidney disease: therapeutic alternatives. Kidney Int Suppl (2005) 0.83
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant (2014) 0.83
Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease. Pediatr Nephrol (2014) 0.82
Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab (2013) 0.82
Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice. Semin Dial (2004) 0.81
Expression of DGCR8-dependent microRNAs is indispensable for osteoclastic development and bone-resorbing activity. J Cell Biochem (2014) 0.81
In vivo transplantation of neonatal ovine neocartilage allografts: determining the effectiveness of tissue transglutaminase. J Knee Surg (2005) 0.81
Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. Am J Nephrol (2014) 0.81
Endogenous BMP-7 is a critical molecular determinant of the reversibility of obstruction-induced renal injuries. Am J Physiol Renal Physiol (2011) 0.81
Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cells. Kidney Int (2002) 0.80
Vitamin D in kidney disease: pathophysiology and the utility of treatment. Endocrinol Metab Clin North Am (2010) 0.79
Parathyroid hormone assay: problems and opportunities. Pediatr Nephrol (2007) 0.79
Challenges in the therapy of secondary hyperparathyroidism. Ther Apher Dial (2005) 0.78
The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder. Transplantation (2016) 0.78
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor. Am J Nephrol (2015) 0.78
Role of bone biopsy in renal osteodystrophy. Saudi J Kidney Dis Transpl (2009) 0.77
Vitamin D in kidney disease: pathophysiology and the utility of treatment. Rheum Dis Clin North Am (2012) 0.76
Percutaneous technique of presternal peritoneal dialysis catheter placement. Semin Dial (2004) 0.75
New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Metab (2006) 0.75
Role of interventional nephrology in dialysis access management. Mo Med (2011) 0.75
[significance of PTH (1-84) assay in the management of chronic renal failure and the current status and future of the treatment of renal osteopathy]. Clin Calcium (2005) 0.75
Cutting balloon angioplasty for resistant venous anastomotic stenoses. Semin Dial (2005) 0.75